Genzyme’s Cerdelga gets European marketing authorization for Gaucher Disease

The European Commission (EC) has granted marketing authorization for Genzyme’s Cerdelga (eliglustat) capsules, a first line oral therapy for certain adults living with Gaucher disease type 1.

Category One, Showcase, status, Uncategorized, What's Hot